2. Academic Validation
  3. Treatment guidelines in psoriatic arthritis

Treatment guidelines in psoriatic arthritis

  • Rheumatology (Oxford). 2020 Mar 1;59(Suppl 1):i37-i46. doi: 10.1093/rheumatology/kez383.
Alexis Ogdie 1,  Laura C Coates 2,  Dafna D Gladman 3
Affiliations

Affiliations

  • 1 Departments of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • 3 University of Toronto, Department of Medicine, University of Toronto, Toronto Western Hospital, Krembil Research Institute, Toronto, ON, Canada.
PMID: 32159790 DOI: 10.1093/rheumatology/kez383
Abstract

Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The treatment of PsA has changed substantially over the past 10 years. Clinical practice guidelines are developed to help busy clinicians rapidly integrate evolving knowledge of therapeutic management into practice. In this review, we compare PsA treatment recommendations or guidelines developed by one national organization [ACR and National Psoriasis Foundation (NPF) in 2018], one regional organization (EULAR in 2015), and one international organization (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis in 2015). We examine the development of guidelines in PsA more broadly and examine similarities and differences in the three sets of recommendations.

Keywords

outcomes; psoriatic arthritis; therapy; treat-to-target; treatment guidelines.

Figures